CompaniesLaboratoires Théa

Laboratoires Théa

active

Clermont Ferrand, France

Founded 1994

Website

About

Eye-care Products

Areas of Focus

Categories

Small Molecule Pharmaceutical

Clinical Trials (92)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

13,299

By Phase

PHASE2: 9NA: 37PHASE4: 11PHASE3: 15PHASE1: 8PHASE1/PHASE2: 3PHASE2/PHASE3: 2

By Status

COMPLETED: 67RECRUITING: 7TERMINATED: 7UNKNOWN: 5NOT_YET_RECRUITING: 3ACTIVE_NOT_RECRUITING: 2WITHDRAWN: 1

Clinical Trials Pipeline90 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Today

NCT00357019

Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis

Phase: Phase 4

Role: Lead Sponsor

Start: Apr 30, 2001

Completion: Oct 31, 2002

NCT00357539

Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2002

Completion: Mar 31, 2002

NCT00357292

Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2002

Completion: Apr 30, 2002

NCT00356850

Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2002

Completion: Jun 30, 2002

NCT00357383

Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2002

Completion: Oct 31, 2002

NCT00356772

Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2003

Completion: Mar 31, 2003

NCT00356720

Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2004

Completion: May 31, 2004

NCT00357773

Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2004

Completion: Jun 30, 2005

NCT00357201

Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2004

Completion: May 31, 2005

NCT00159211

Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin

Phase: N/A

Role: Collaborator

Start: May 31, 2005

Completion: May 31, 2007

NCT00348855

Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice

Phase: Phase 4

Role: Collaborator

Start: Nov 30, 2006

Completion: Mar 31, 2010

NCT01494753

Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2008

Completion: Dec 31, 2008

NCT01155219

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Phase: Phase 4

Role: Lead Sponsor

Start: Jul 31, 2008

Completion: Dec 31, 2009

NCT01155999

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2008

Completion: Feb 28, 2011

NCT01156025

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2009

Completion: Jun 30, 2010

NCT01156012

Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2009

Completion: Dec 31, 2010

NCT01089608

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2010

Completion: Jun 30, 2012

NCT01091311

Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Phase: Phase 4

Role: Lead Sponsor

Start: May 31, 2010

Completion: Dec 31, 2010

NCT01189474

Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases

Phase: Phase 4

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Dec 31, 2011

NCT01190397

Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2010

Completion: Nov 30, 2010

NCT01203540

Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients

Phase: Phase 4

Role: Lead Sponsor

Start: Oct 31, 2010

Completion: Jan 31, 2011

NCT01269697

Lutein Influence on Macula of Persons Issued From Amd Parents

Phase: Phase 3

Role: Collaborator

Start: Jan 31, 2011

Completion: Jan 31, 2013

NCT01344083

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2011

Completion: Feb 29, 2012

NCT02101359

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2011

Completion: May 31, 2013

NCT01552174

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice

Phase: N/A

Role: Lead Sponsor

Start: Mar 31, 2012

Completion: Apr 30, 2014

NCT01568593

Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2012

Completion: Mar 31, 2013

NCT01794312

Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 28, 2013

Completion: Dec 19, 2017

NCT01794312

NCT02951585

Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis

Phase: N/A

Role: Lead Sponsor

Start: May 31, 2013

Completion: Oct 31, 2014

NCT02017327

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Phase: Phase 4

Role: Lead Sponsor

Start: Dec 31, 2013

Completion: Jul 31, 2016

NCT02023268

Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2013

Completion: Feb 28, 2015

NCT02278614

Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2014

Completion: Nov 30, 2015

NCT02617095

Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

Phase: N/A

Role: Lead Sponsor

Start: Feb 28, 2015

Completion: Oct 31, 2016

NCT02373397

Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy

Phase: N/A

Role: Collaborator

Start: Mar 31, 2015

Completion: Dec 31, 2017

NCT02976272

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple

Phase: N/A

Role: Collaborator

Start: Jun 7, 2016

Completion: Jan 31, 2021

NCT02976272

NCT02979054

Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking

Phase: N/A

Role: Lead Sponsor

Start: Dec 31, 2016

Completion: Mar 31, 2018

NCT04482465

Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD

Phase: N/A

Role: Collaborator

Start: Apr 20, 2017

Completion: Oct 5, 2017

NCT02739880

Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule

Phase: N/A

Role: Collaborator

Start: Jun 19, 2017

Completion: Feb 13, 2019

NCT03140969

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Phase: Phase 1/2

Role: Lead Sponsor

Start: Oct 16, 2017

Completion: Oct 2, 2019

NCT03329261

Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Phase: Phase 4

Role: Lead Sponsor

Start: Dec 7, 2017

Completion: Dec 20, 2019

NCT03404557

Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC

Phase: N/A

Role: Collaborator

Start: Jan 18, 2018

Completion: Jan 18, 2019

NCT03830359

Efficacy, Safety of T2769 in Dry Eye Disease

Phase: N/A

Role: Lead Sponsor

Start: Sep 1, 2018

Completion: Feb 18, 2019

NCT04050644

Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery

Phase: Phase 4

Role: Collaborator

Start: Oct 30, 2018

Completion: Dec 31, 2024

NCT04050644

NCT03825380

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 23, 2018

Completion: Feb 24, 2021

NCT04803240

Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

Phase: N/A

Role: Lead Sponsor

Start: Apr 1, 2019

Completion: Mar 30, 2020

NCT03874429

Efficacy of T2259 in DED

Phase: N/A

Role: Lead Sponsor

Start: Apr 24, 2019

Completion: Mar 25, 2021

NCT03913130

Extension Study to Study PQ-110-001 (NCT03140969)

Phase: Phase 1/2

Role: Lead Sponsor

Start: May 13, 2019

Completion: Oct 3, 2022

NCT04088006

The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity

Phase: N/A

Role: Lead Sponsor

Start: Sep 3, 2019

Completion: Jul 8, 2020

NCT04780165

Efficacy and Tolerability of Blephademodex Wipes

Phase: N/A

Role: Lead Sponsor

Start: Sep 11, 2019

Completion: May 14, 2020

NCT04078646

Influence of Proteins on the Bioavailability of Carotenoids

Phase: N/A

Role: Collaborator

Start: Oct 11, 2019

Completion: Jun 30, 2021

NCT04147689

Evaluation of the Efficacy and Safety of Hyaluronic Acid Injection in Labia Majora for Volume Restoration

Phase: N/A

Role: Lead Sponsor

Start: Nov 18, 2019

Completion: Mar 30, 2022

NCT04166292

The Evaluation of Efficacy and Safety of Stylage® XL Lidocaïne for the Restoration and/or Augmentation of Facial Volume

Phase: N/A

Role: Lead Sponsor

Start: Nov 21, 2019

Completion: Aug 7, 2021

NCT04219722

Efficacy and Safety of Hyaluronic Acid Injection on Symptoms of Vulvovaginal Atrophy in Postmenopausal Women

Phase: N/A

Role: Lead Sponsor

Start: Jan 21, 2020

Completion: Jun 18, 2022

NCT03739255

Facilitation of Corneal Re-epithelialization After Photorefractive Keratectomy

Phase: N/A

Role: Collaborator

Start: Mar 1, 2020

Completion: Jul 31, 2021

NCT04379297

COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)

Phase: N/A

Role: Collaborator

Start: Apr 10, 2020

Completion: Sep 30, 2022

NCT04499820

Effect of OMEGA3 Supplementation in Diabetic Retinopathy

Phase: N/A

Role: Collaborator

Start: Jun 26, 2020

Completion: Nov 25, 2024

NCT04596605

Gastrointestinal Tolerance Assessment of T2309

Phase: N/A

Role: Lead Sponsor

Start: Jul 15, 2020

Completion: Mar 4, 2021

NCT04552964

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Phase: N/A

Role: Lead Sponsor

Start: Sep 25, 2020

Completion: Apr 27, 2021

NCT04778436

Macula Evolution in Patients With AMD Taking Oral Food Supplementation

Phase: N/A

Role: Lead Sponsor

Start: Jan 13, 2021

Completion: Jan 24, 2022

NCT04713917

Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment

Phase: N/A

Role: Collaborator

Start: Feb 21, 2021

Completion: Feb 1, 2024

NCT04898387

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 26, 2021

Completion: May 30, 2023

NCT04844216

Effectiveness and Safety of STYLAGE® L Lidocaïne in the Treatment of Nasolabial Folds

Phase: N/A

Role: Lead Sponsor

Start: Apr 16, 2021

Completion: Jul 6, 2022

NCT04861766

Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults

Phase: N/A

Role: Lead Sponsor

Start: May 6, 2021

Completion: Mar 31, 2023

NCT04813614

Effectiveness and Safety of STYLAGE® M Lidocaïne for Lips' Volume Augmentation and/or Redefinition of the Outline of the Lips (SMILE)

Phase: N/A

Role: Lead Sponsor

Start: May 31, 2021

Completion: Jul 12, 2022

NCT04957329

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Phase: Phase 4

Role: Collaborator

Start: Sep 1, 2021

Completion: Dec 31, 2026

NCT04957329

NCT05009381

Effectiveness and Safety of STYLAGE® XXL for Chin Augmentation in Chinese Adults

Phase: N/A

Role: Lead Sponsor

Start: Sep 10, 2021

Completion: Aug 31, 2023

NCT05085964

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 16, 2021

Completion: Oct 18, 2022

NCT05087732

Effectiveness and Safety of STYLAGE® M LIDOCAINE Versus STYLAGE® M in Filling Nasolabial Folds

Phase: N/A

Role: Lead Sponsor

Start: Oct 19, 2021

Completion: Nov 24, 2022

NCT05146310

Prospective, Multicenter, Non-comparative Clinical Investigation to Support Safety & Effectiveness of I.SPACE®

Phase: N/A

Role: Lead Sponsor

Start: Dec 6, 2021

Completion: Mar 1, 2023

NCT05158296

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Phase: Phase 2/3

Role: Lead Sponsor

Start: Dec 8, 2021

Completion: Oct 12, 2022

NCT05176717

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Phase: Phase 2/3

Role: Lead Sponsor

Start: Dec 15, 2021

Completion: Aug 2, 2022

NCT05356728

Comparison of Two Types of Artificial Tears

Phase: N/A

Role: Collaborator

Start: Mar 11, 2022

Completion: Dec 31, 2023

NCT05355454

Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face

Phase: N/A

Role: Lead Sponsor

Start: Jun 6, 2022

Completion: Apr 25, 2025

NCT05397600

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 22, 2022

Completion: Mar 7, 2024

NCT05389267

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jul 5, 2022

Completion: Dec 31, 2024

NCT05622435

Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers

Phase: N/A

Role: Lead Sponsor

Start: Oct 17, 2022

Completion: Nov 10, 2022

NCT05747456

Study of a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face (FaceHyal)

Phase: N/A

Role: Lead Sponsor

Start: Feb 22, 2023

Completion: Sep 2, 2025

NCT05729594

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 27, 2023

Completion: Apr 5, 2023

NCT05809739

Effectiveness and Safety of STYLAGE® HYDRO in the Treatment of Face, Neckline Area and Neck

Phase: N/A

Role: Lead Sponsor

Start: Feb 28, 2023

Completion: Feb 1, 2024

NCT05668455

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Phase: Phase 3

Role: Collaborator

Start: May 12, 2023

Completion: Jul 20, 2026

NCT05931861

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Phase: N/A

Role: Lead Sponsor

Start: Aug 15, 2023

Completion: Dec 4, 2023

NCT05965778

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Phase: N/A

Role: Lead Sponsor

Start: Oct 2, 2023

Completion: Aug 31, 2024

NCT06394973

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 5, 2024

Completion: May 31, 2025

NCT06375499

Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Phase: N/A

Role: Lead Sponsor

Start: Sep 17, 2024

Completion: Jan 6, 2025

NCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene